Abiomed, Inc. announced that its product Impella 5.0 has received FDA 510(K) approval to provide circulatory support for periods of up to six hours. Apart from this product Impella LD Circulatory Support Devices has also received 510(K) approval. These minimally invasive catheter-based pumps, similar to already approved Impella 2.5 are designed to provide temporary circulatory support and reduce the workload of the heart muscle. They will be available in the size of a pencil with a small nine French catheter, which drives up to five liters of blood flow per minute, a flow rate typically adequate to fully support the average adult. The Impella 5.0 helps cardiologists and surgeons with the clinical flexibility to select and deploy circulatory support devices for patients based on the severity of cardiac dysfunction, the amount of flow needed while addressing the dysfunction, and the preferred implant approach. In application, Impella is designed to increase the flow delivered by the heart, which can potentially reduce the work of the heart and augment coronary flow.